Frontiers in Immunology
Patients with primary immunodeficiency disorders (PID) have an increased risk from acute and chronic Epstein-Barr Virus (EBV) viral infections and EBV-associated malignancies. Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients with PID, but EBV-related complications are common in the immediate post-transplant period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with EBV-specific T cells is a promising therapeutic strategy for patients with PID both before and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, the clinical outcomes, and the ongoing challenges for future development of the strategy. © 2018 McLaughlin, Bollard and Keller.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
McLaughlin, L., Bollard, C., & Keller, M. D. (2018). Adoptive T cell therapy for Epstein-Barr virus complications in patients with primary immunodeficiency disorders. Frontiers in Immunology, 9 (). http://dx.doi.org/10.3389/fimmu.2018.00556